Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807825 | 0.78 | — | — | |
| SCHEMBL12872504 | 0.78 | HTR1A (0.53) | MAPTALDH1A1HTR1A | |
| SCHEMBL25912762 | 0.77 | L3MBTL1 (0.33) | MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL14319076 | 0.77 | SMN1; SMN2 (0.39) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20346243 | 0.76 | HRH3 (0.44) | MAPT | |
| SCHEMBL25895293 | 0.76 | CHRNB2 (0.38) | MAPTALDH1A1HTR1AKMT2AMEN1 | |
| SCHEMBL21733089 | 0.76 | MAPT (0.33) | MAPTHTR1AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20234147 | 0.74 | HRH3 (0.44) | MAPTALDH1A1 | |
| SCHEMBL22152624 | 0.73 | KDM4E (0.44) | ALDH1A1HTR1A | |
| SCHEMBL18705032 | 0.73 | HRH3 (0.36) | MAPTALDH1A1L3MBTL1GRM5HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MAPT 3764/4885ALDH1A1 3951/4885L3MBTL1 3587/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MAPT 3364/4885ALDH1A1 4437/4885L3MBTL1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.